Changes in Beneficial Ownership · 4
Apollomics Inc.
APLMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-15
- Issuer
- Apollomics Inc.
- Issuer CIK
- 0001944885
- Trading symbol
- APLM
Reporting owner 1
- Name
- Jan Chen-Huan
- Reporting owner CIK
- 0002115367
- Relationship
- Director
- Address
- 989 E HILLSDALE BLVD, SUITE 220, FOSTER CITY, CA, 94404
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| CLASS A ORDINARY SHARES | 2026-06-15 | M · Form 4 | 500 | A | 0 | 1,500 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-06-15 | M · Form 4 | 500 | D | 0 | [F2] | [F2] | CLASS A ORDINARY SHARES | 500 | 500 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Each restricted stock unit represents a contingent right to receive one Class A Ordinary Share↩ 1
- F2
- RSUs were granted and previously reported on a Form 3 filed March 18, 2026 and a Form 3/A filed April 14, 2026. Of the initial RSU grant, 500 shares vested on each of February 9, 2026, March 15, 2026 and June 15, 2026 and an additional 500 shares will vest on September 15, 2026. This transaction represents the vesting of 500 RSUs on June 15, 2026.↩ 1↩ 2
Signature 1
- Signed
- /s/ Alison M. Pear, Attorney-In-Fact
- Date
- 2026-06-16
Company context
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.